ERYTECH Pharma forms research collaboration with Queen's University to develop treatment for arginase-1 deficiency.
M2 PHARMA-July 12, 2017-ERYTECH Pharma forms research collaboration with Queen's University to develop treatment for arginase-1 deficiency
(C)2017 M2 COMMUNICATIONS
French clinical-stage biopharmaceutical company ERYTECH Pharma (ADR:EYRYY) has entered into a research collaboration with Queen's University in Canada, the company reported on Wednesday.
The collaboration aims to enhance the preclinical development of ERYTECH's eryminase programme, with a particular predominance placed on the treatment of arginase-1 deficiency, a rare and severe metabolic disorder related to arginine metabolism.
It will utilise the expertise of Queen's University as well as ERYTECH's ERYCAPS platform technology, with the end goal of generating in-vivo proof-of-concept data in an arginase-1 deficiency animal model.
Arginase-1 deficiency is a rare, inherited disorder that affects the urea cycle due to a mutation in the arginase-1 gene. This manifests in the accumulation of toxic levels of the amino acid arginine in the blood.
Dr Alexander Scheer, PhD, chief scientific officer of ERYTECH, commented: "This is our second collaboration in the field of rare metabolic diseases that underscores the scope of our platform and its applicability to highly specialized and rare conditions beyond oncology. We are very pleased to enter this collaboration with Queen's University and look forward to working closely on this important program with Dr Funk who specialises in research related to urea cycle disorders."
((Comments on this story may be sent to firstname.lastname@example.org))
|Printer friendly Cite/link Email Feedback|
|Date:||Jul 12, 2017|
|Previous Article:||Vifor Pharma announces three new clinical trials for Ferinject.|
|Next Article:||Zydus Cadila granted final FDA approval to commercialise Memantine Hydrochloride.|